Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 273Carcinoma, Non-Small-Cell Lung 244Carcinoma, Renal Cell 144Neoplasms 99Neoplasm Metastasis 99Squamous Cell Carcinoma of Head and Neck 88Carcinoma, Hepatocellular 87Colorectal Neoplasms 82Lung Neoplasms 77Stomach Neoplasms 59Pancreatic Neoplasms 56Carcinoma, Transitional Cell 50Hodgkin Disease 47Urinary Bladder Neoplasms 42Head and Neck Neoplasms 42Breast Neoplasms 40Ovarian Neoplasms 37Triple Negative Breast Neoplasms 34Small Cell Lung Carcinoma 33Brain Neoplasms 33Sarcoma 32Prostatic Neoplasms 32Glioblastoma 32Kidney Neoplasms 29Recurrence 28Multiple Myeloma 25Esophageal Neoplasms 24Uveal Melanoma 23Skin Neoplasms 23Uterine Cervical Neoplasms 22

Interventions

relacorilant 3pembrolizumab 3cabozantinib 2Mifepristone 2Corlux 2veliparib 1tariquidar 1olaparib 1lutetium Lu 177 dotatate 1fludarabine phosphate 1fludarabine 1Temozolomide 1Specimen Handling 1Pharmacogenomic Variants 1Pharmacogenomic Testing 1Osilodrostat 1Nivolumab 1Mesna 1Magnetic Resonance Spectroscopy 1Gefitinib 1Floxuridine 1Dexamethasone 1Cyclophosphamide 1Capecitabine 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adrenal Cortex Neoplasms × Nivolumab × Clear all
NCT02720484 2019-05-01

Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer

Northwestern University

Phase 2 Terminated
10 enrolled 11 charts

Adrenal Cortex Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡